Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer
ConclusionsOur results suggest that HER2 signaling might suppress immune cell activation in the GC TME by inhibiting STING signaling in tumor cells in HER2-positive GC. (Source: Gastric Cancer)
Source: Gastric Cancer - August 5, 2023 Category: Gastroenterology Source Type: research
Circulating hormones and risk of gastric cancer by subsite in three cohort studies
ConclusionsSome obesity-related hormones influence CGC and NCGC risk. (Source: Gastric Cancer)
Source: Gastric Cancer - July 16, 2023 Category: Gastroenterology Source Type: research
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action
ConclusionsAvailable methods can lead to conflicting results in MSI-H/dMMR evaluation between endoscopic biopsies and surgical samples of gastroesophageal adenocarcinoma. Strategies aiming to improve the reliability of assessment should be primarily focused on the optimization of tissue collection and management during endoscopy and adequate training of dedicated gastrointestinal pathologists within the multidisciplinary team. (Source: Gastric Cancer)
Source: Gastric Cancer - June 29, 2023 Category: Gastroenterology Source Type: research
Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma
ConclusionsSevere gastric atrophy and macrocytosis should be noted in the development of metachronous primary GC after ER for esophageal SCC. In particular, macrocytosis at the timing of ER was considered an important predictor.Clinical trials registry number: UMIN000001676. (Source: Gastric Cancer)
Source: Gastric Cancer - June 27, 2023 Category: Gastroenterology Source Type: research
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
ConclusionsNeoadjuvant imatinib treatment is an effective treatment option for gastric GISTs 10 cm or larger. Postoperative imatinib treatment is recommended even after R0 resection to minimize recurrence. (Source: Gastric Cancer)
Source: Gastric Cancer - June 23, 2023 Category: Gastroenterology Source Type: research
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model
ConclusionThe present study confirmed that auramycin G displayed a prominent antitumor activity in gastric tumor models, both in vitro and in vivo. Moreover, it was confirmed that auramycin G played a specific role in certain gastric cancer cell types, while the mechanism was validated to be associated with angiogenesis- and lymphangiogenesis-related pathway suppression.Graphical abstract (Source: Gastric Cancer)
Source: Gastric Cancer - June 21, 2023 Category: Gastroenterology Source Type: research
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
ConclusionAlthough eight cycles of DS therapy may prolong prognosis, the present study did not provide a clear conclusion as to how many DS therapy cycles are needed to improve prognosis after D2 gastrectomy for stage III gastric cancer.Trial registrationRegistration number: UMIN00000714 and UMIN000004440. (Source: Gastric Cancer)
Source: Gastric Cancer - June 19, 2023 Category: Gastroenterology Source Type: research
Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer
ConclusionsPDT elicits an anti-tumour response through various mechanisms and is promising as an adjuvant to enhance ICI benefit. (Source: Gastric Cancer)
Source: Gastric Cancer - June 19, 2023 Category: Gastroenterology Source Type: research
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
ConclusionAlthough eight cycles of DS therapy may prolong prognosis, the present study did not provide a clear conclusion as to how many DS therapy cycles are needed to improve prognosis after D2 gastrectomy for stage III gastric cancer.Trial registrationRegistration number: UMIN00000714 and UMIN000004440. (Source: Gastric Cancer)
Source: Gastric Cancer - June 19, 2023 Category: Gastroenterology Source Type: research
